journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/29242042/neoadjuvant-chemotherapy-in-breast-cancer-more-than-just-downsizing
#1
Marloes G M Derks, Cornelis J H van de Velde
No abstract text is available yet for this article.
December 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29242041/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast-cancer-meta-analysis-of-individual-patient-data-from-ten-randomised-trials
#2
(no author information available yet)
BACKGROUND: Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the influence of tumour characteristics on outcome with a collaborative meta-analysis of individual patient data from relevant randomised trials. METHODS: We obtained information about prerandomisation tumour characteristics, clinical tumour response, surgery, recurrence, and mortality for 4756 women in ten randomised trials in early breast cancer that began before 2005 and compared NACT with the same chemotherapy given postoperatively...
December 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29233560/tumour-infiltrating-lymphocytes-in-breast-cancer-increasing-clinical-relevance
#3
Roberto Salgado, Sherene Loi
No abstract text is available yet for this article.
December 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29233559/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast-cancer-a-pooled-analysis-of-3771-patients-treated-with-neoadjuvant-therapy
#4
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang D Schmitt, Jens-Uwe Blohmer, Thomas Karn, Berit M Pfitzner, Sherko Kümmel, Knut Engels, Andreas Schneeweiss, Arndt Hartmann, Aurelia Noske, Peter A Fasching, Christian Jackisch, Marion van Mackelenbergh, Peter Sinn, Christian Schem, Claus Hanusch, Michael Untch, Sibylle Loibl
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, but their role in luminal breast cancer and the effect of TILs on prognosis in all subtypes is less clear. Here, we assessed the relevance of TILs for chemotherapy response and prognosis in patients with TNBC, HER2-positive breast cancer, and luminal-HER2-negative breast cancer. METHODS: Patients with primary breast cancer who were treated with neoadjuvant combination chemotherapy were included from six randomised trials done by the German Breast Cancer Group...
December 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29233558/combined-androgen-blockade-for-salivary-gland-carcinoma
#5
Elizabeth Gourd
No abstract text is available yet for this article.
December 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29233557/bgj398-for-fgfr-altered-advanced-cholangiocarcinoma
#6
Judith A Gilbert
No abstract text is available yet for this article.
December 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29223745/buparlisib-plus-fulvestrant-in-postmenopausal-women-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-progressing-on-or-after-mtor-inhibition-belle-3-a-randomised-double-blind-placebo-controlled-phase-3-trial
#7
Angelo Di Leo, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per E Lønning, Wolfgang Janni, Ruth O'Regan, Marie-Ange Mouret-Reynier, Dimitar Kalev, Daniel Egle, Tibor Csőszi, Roberto Bordonaro, Thomas Decker, Vivianne C G Tjan-Heijnen, Sibel Blau, Alessio Schirone, Denis Weber, Mona El-Hashimy, Bharani Dharan, Dalila Sellami, Thomas Bachelot
BACKGROUND: Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell growth and proliferation but elicit AKT phosphorylation via a feedback activation pathway, potentially leading to resistance to mTOR inhibitors. We evaluated the efficacy and safety of buparlisib plus fulvestrant in patients with advanced breast cancer who were pretreated with endocrine therapy and mTOR inhibitors...
December 6, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29217289/javelin-avelumab-another-spear-to-fight-urothelial-carcinoma
#8
Aly-Khan A Lalani, Bradley A McGregor, Guru P Sonpavde, Toni K Choueiri
No abstract text is available yet for this article.
December 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29217288/avelumab-in-metastatic-urothelial-carcinoma-after-platinum-failure-javelin-solid-tumor-pooled-results-from-two-expansion-cohorts-of-an-open-label-phase-1-trial
#9
Manish R Patel, John Ellerton, Jeffrey R Infante, Manish Agrawal, Michael Gordon, Raid Aljumaily, Carolyn D Britten, Luc Dirix, Keun-Wook Lee, Mathew Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Arnold B Gelb, Junyuan Xiong, Galit Rosen, James L Gulley, Andrea B Apolo
BACKGROUND: The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options for patients with locally advanced or metastatic urothelial carcinoma. Avelumab, a human monoclonal anti-PD-L1 antibody, has shown promising antitumour activity and safety in this disease. We aimed to assess the safety profile in patients (both post-platinum therapy and cisplatin-naive) treated with avelumab and to assess antitumour activity of this drug in post-platinum patients...
December 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29198474/identifying-precursor-lesions-of-pancreatic-cancer
#10
Priya Venkatesan
No abstract text is available yet for this article.
November 30, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29198473/upfront-resection-of-pancreatic-intraductal-neoplasms
#11
Elizabeth Gourd
No abstract text is available yet for this article.
November 30, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29198472/soft-tissue-sarcoma-risk-in-childhood-cancer-survivors
#12
Manjulika Das
No abstract text is available yet for this article.
November 30, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29175151/osimertinib-improves-progression-free-survival-in-nsclc
#13
Robert Stirrups
No abstract text is available yet for this article.
November 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29175150/131i-radiation-exposure-and-thyroid-cancer
#14
Talha Khan Burki
No abstract text is available yet for this article.
November 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29175149/neoadjuvant-trastuzumab-pertuzumab-and-chemotherapy-versus-trastuzumab-emtansine-plus-pertuzumab-in-patients-with-her2-positive-breast-cancer-kristine-a-randomised-open-label-multicentre-phase-3-trial
#15
Sara A Hurvitz, Miguel Martin, W Fraser Symmans, Kyung Hae Jung, Chiun-Sheng Huang, Alastair M Thompson, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean-François Boileau, Matthias W Beckmann, Karen Afenjar, Rodrigo Fresco, Hans-Joachim Helms, Jin Xu, Yvonne G Lin, Joseph Sparano, Dennis Slamon
BACKGROUND: HER2-targeted treatments have improved outcomes in patients with HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however, some patients remain at risk of relapse or death for many years after treatment of early-stage disease. Therefore, new strategies are needed. We did a phase 3 trial to assess a neoadjuvant regimen for HER2-positive breast cancer that replaces traditional systemic chemotherapy with targeted treatment. METHODS: We did a randomised, open-label phase 3 KRISTINE trial in 68 Translational Research In Oncology centres (hospitals and specialty cancer centres in Asia, Europe, USA, and Canada)...
November 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29175148/lenalidomide-plus-dexamethasone-in-multiple-myeloma
#16
Manjulika Das
No abstract text is available yet for this article.
November 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29175147/durvalumab-boosts-progression-free-survival-in-nsclc
#17
Elizabeth Gourd
No abstract text is available yet for this article.
November 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29175146/early-her2-positive-breast-cancers-time-for-a-new-revolution
#18
Joseph Gligorov
No abstract text is available yet for this article.
November 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29174310/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii-iiia-n1-n2-egfr-mutant-nsclc-adjuvant-ctong1104-a-randomised-open-label-phase-3-study
#19
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Ke Fei, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Xue-Ning Yang, Qing Zhou, Yi-Long Wu
BACKGROUND: Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II-IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data suggest patients with EGFR-mutant stage IB-IIIA resected NSCLC could benefit from adjuvant EGFR tyrosine kinase inhibitor treatment. We aimed to compare the efficacy of adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected EGFR-mutant stage II-IIIA (N1-N2) NSCLC. METHODS: We did a randomised, open-label, phase 3 trial at 27 centres in China...
November 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29174309/lung-cancer-s-real-adjuvant-egfr-targeted-therapy-questions
#20
Terry L Ng, D Ross Camidge
No abstract text is available yet for this article.
November 21, 2017: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"